title: Inhibition of human vascular endothelial cell migration and capillary-like tube formation by the microtubule-stabilizing agent peloruside A.
abstract: Peloruside A is a microtubule-stabilizing agent that is currently under investigation as a potential anticancer agent. Peloruside A binds to a site on β-tubulin that is distinct to that of the taxanes (paclitaxel and docetaxel) and the epothilones. An attractive clinical quality of microtubule-stabilizing agents is their ability to target multiple mechanisms of tumour growth. In addition to inducing tumour cell apoptosis by arresting cells in mitosis, microtubule-stabilizing agents also inhibit angiogenesis, a process needed by tumor cells for growth and metastasis. In this study, the effects of peloruside A on endothelial cell processes important for angiogenesis were assessed in comparison to docetaxel. Both peloruside A and docetaxel potently inhibited the proliferation of human umbilical vein endothelial cells, with IC50 values of 1.4 and 1.7 nM, respectively. Peloruside also potently blocked endothelial cell migration during wound closure and the three-dimensional organization of the endothelial cells into capillary-like tubes. In the wound scratch assay, peloruside A inhibited wound recovery with an IC50 of 6.3 nM after 18 h. Docetaxel was approximately 3-fold more potent than peloruside A. The number of capillary-like tubes that formed after 16 h culture in Matrigel™ was also inhibited in a dose-dependent manner with an IC50 of 4.5 nM. Docetaxel was about 2-fold more potent than peloruside A in preventing tube formation. This inhibition of endothelial cell function occurred at relatively non-cytotoxic concentrations over the 16-18 h incubations for both stabilizing agents, suggesting that anti-angiogenic effects are likely to occur before therapeutically relevant doses begin to inhibit tumor growth or adverse side effects develop.
authors.affiliation: Centre for Biodiscovery and Schools of Biological Sciences, Victoria University of Wellington, PO Box 600, Wellington, New Zealand.
authors.forename: Ariane
authors.initials: A
authors.lastname: Chan
authors.forename: A Jonathan
authors.initials: AJ
authors.lastname: Singh
authors.forename: Peter T
authors.initials: PT
authors.lastname: Northcote
authors.forename: John H
authors.initials: JH
authors.lastname: Miller
mesh_terms: D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000494:pharmacology*; D002465:Cell Movement / Q000187:drug effects*; D049109:Cell Proliferation / Q000187:drug effects; D000077143:Docetaxel; D061307:Human Umbilical Vein Endothelial Cells / Q000166:cytology* / Q000187:drug effects; D006801:Humans; D007783:Lactones / Q000494:pharmacology*; D008870:Microtubules / Q000187:drug effects / Q000378:metabolism*; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D043823:Taxoids / Q000494:pharmacology
chemical_list: D019086:Bridged Bicyclo Compounds, Heterocyclic; D007783:Lactones; D043823:Taxoids; C414085:peloruside A; D000077143:Docetaxel
references.citation: Anticancer Agents Med Chem. 2013 Sep;13(7):1057-68
references.pmid: 23343081
references.citation: Cancer Res. 2002 Jun 15;62(12 ):3356-60
references.pmid: 12067973
references.citation: Nat Cell Biol. 2007 Mar;9(3):299-309
references.pmid: 17310241
references.citation: Mol Cancer Ther. 2013 Dec;12(12):2837-46
references.pmid: 24107446
references.citation: Langenbecks Arch Surg. 2007 May;392(3):371-9
references.pmid: 17458577
references.citation: Exp Biol Med (Maywood). 2007 May;232(5):607-13
references.pmid: 17463156
references.citation: Invest New Drugs. 2012 Feb;30(1):121-9
references.pmid: 20862516
references.citation: Traffic. 2009 Mar;10(3):268-74
references.pmid: 19175539
references.citation: Mol Pharmacol. 2006 Apr;69(4):1207-15
references.pmid: 16415178
references.citation: N Engl J Med. 2004 Jun 3;350(23 ):2335-42
references.pmid: 15175435
references.citation: Nat Prod Rep. 2014 Mar;31(3):335-55
references.pmid: 24481420
references.citation: Nat Rev Drug Discov. 2007 Apr;6(4):273-86
references.pmid: 17396134
references.citation: Traffic. 2004 Jul;5(7):470-7
references.pmid: 15180824
references.citation: Invest New Drugs. 2011 Aug;29(4):615-26
references.pmid: 20169398
references.citation: Mol Cancer Ther. 2002 Nov;1(13):1191-200
references.pmid: 12479700
references.citation: Clin Cancer Res. 2009 Apr 15;15(8):2594-601
references.pmid: 19351751
references.citation: N Engl J Med. 1971 Nov 18;285(21):1182-6
references.pmid: 4938153
references.citation: J Org Chem. 2000 Jan 28;65(2):445-9
references.pmid: 10813954
references.citation: Nat Rev Cancer. 2004 Apr;4(4):253-65
references.pmid: 15057285
references.citation: Cancer Res. 2006 Aug 15;66(16):8192-9
references.pmid: 16912198
references.citation: Invest New Drugs. 2011 Aug;29(4):544-53
references.pmid: 20107863
references.citation: Int J Oncol. 2002 Aug;21(2):417-25
references.pmid: 12118340
references.citation: Biochemistry. 2002 Jul 23;41(29):9109-15
references.pmid: 12119025
references.citation: J Biol Chem. 2010 Oct 15;285(42):32242-50
references.pmid: 20696757
references.citation: Cancer Chemother Pharmacol. 2011 Jul;68(1):117-26
references.pmid: 20848285
references.citation: Drug Discov Today. 2014 Jul;19(7):824-9
references.pmid: 24201225
references.citation: Cancer Res. 2002 Dec 1;62(23 ):6938-43
references.pmid: 12460910
references.citation: Nat Commun. 2015 Jan 22;6:6135
references.pmid: 25609142
references.citation: Anticancer Agents Med Chem. 2013 Jan;13(1):147-58
references.pmid: 22583426
references.citation: Acc Chem Res. 2014 Aug 19;47(8):2682-91
references.pmid: 25052294
references.citation: Biochem Res Int. 2012;2012:832059
references.pmid: 22811914
references.citation: Annu Rev Med. 1997;48:353-74
references.pmid: 9046968
references.citation: Bioorg Med Chem. 2014 Sep 15;22(18):5050-9
references.pmid: 24650703
references.citation: Cytoskeleton (Hoboken). 2014 Jan;71(1):46-60
references.pmid: 24155271
references.citation: Int J Mol Sci. 2012;13(4):4906-19
references.pmid: 22606019
references.citation: Angew Chem Int Ed Engl. 2014 Feb 3;53(6):1621-5
references.pmid: 24470331
references.citation: Trends Cell Biol. 2005 Feb;15(2):76-83
references.pmid: 15695094
references.citation: Mol Cancer Ther. 2006 Sep;5(9):2348-57
references.pmid: 16985069
references.citation: Nat Rev Cancer. 2002 Oct;2(10):727-39
references.pmid: 12360276
references.citation: Semin Cell Dev Biol. 2011 Dec;22(9):968-74
references.pmid: 22001384
references.citation: Clin Cancer Res. 1996 Nov;2(11):1843-9
references.pmid: 9816139
references.citation: Anticancer Drug Des. 2001 Apr-Jun;16(2-3):155-66
references.pmid: 11962513
references.citation: Mol Cancer Ther. 2003 Dec;2(12):1303-11
references.pmid: 14707271
references.citation: Cancer Res. 2004 Aug 1;64(15):5063-7
references.pmid: 15289305
references.citation: Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11809-14
references.pmid: 15282376